A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer

Abstract Despite the availability of numerous treatment options for metastatic estrogen receptor positive breast cancer, additional strategies are needed, particularly when tumors become endocrine resistant. This phase Ib/II study examined the clinical activity and safety of the novel combination of...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessica Mezzanotte-Sharpe, Brandie C. Taylor, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Andres A. Ocampo, Jacey L. Marshall, Julia A. Steele, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko, Laura C. Kennedy
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00773-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41523-025-00773-4

Similar Items